Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 12Multiple Myeloma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Hematologic Neoplasms 6Neuroblastoma 5Hodgkin Disease 5Retinoblastoma 4Lymphoma, Non-Hodgkin 4Graft vs Host Disease 4Anemia, Refractory, with Excess of Blasts 4Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Recurrence 2Primary Myelofibrosis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Leukemia 2Ganglioneuroblastoma 2Anemia, Aplastic 2beta-Thalassemia 1Venentoclax 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Rhabdomyosarcoma 1

Interventions

Cyclophosphamide 8fludarabine 6cabozantinib 5Temozolomide 4Doxorubicin 4Zoledronic Acid 3X-Rays 3Vincristine 3Methotrexate 3Ifosfamide 3Gemcitabine 3Cisplatin 3irinotecan sucrosofate 2atezolizumab 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiosurgery 2Phantoms, Imaging 2Mesna 2Magnetic Resonance Spectroscopy 2Irinotecan 2Eflornithine 2Disulfiram 2Biopsy 2vactosertib 1trilaciclib 1trametinib 1talazoparib 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Osteosarcoma × Melphalan × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡